Researchers in California have discovered that administering semaglutide, the active ingredient in Ozempic, to female mice can extend their lifespan by 12%. The study began with mice at 20 months old, which is approximately equivalent to 60 years in human age. Mice receiving semaglutide lived an average of 834 days, compared to 742 days for the control group that was given saline and unlimited standard food. Notably, all the mice in the study were neither obese nor diabetic.
Previous research indicated that reducing calorie intake can prolong life and mitigate some aspects of aging. This motivated the scientists to explore semaglutide's potential, as the drug suppresses appetite without the need for constant self-discipline.
In an additional segment of the study, semaglutide-treated mice exhibited enhancements in memory, coordination, and stamina, alongside improved glucose management. Furthermore, these mice experienced lower levels of chronic inflammation, a reduction in senescent cells, diminished DNA damage, and enhanced mitochondrial performance.
In a different experiment, researchers evaluated semaglutide against calorie restriction over a five-month period. One group was treated with the drug, another had their food intake limited by 24%, and a third group ate freely. Both the drug and calorie restriction yielded similar outcomes in several areas. However, semaglutide outperformed in assessments related to exploratory behavior, spatial memory, and glucose regulation.
The study does not provide a direct lifespan comparison between the drug and dietary restrictions, a point noted by independent scientists. The authors of the study have indicated that such an experiment is currently in progress. "I can't predict the outcomes; they often surprise us," remarked lead researcher Danica Chen. Would you consider using Ozempic for a longer life?
Informational material. 18+.
